<SEC-DOCUMENT>0001193125-16-528595.txt : 20160404
<SEC-HEADER>0001193125-16-528595.hdr.sgml : 20160404
<ACCEPTANCE-DATETIME>20160404074330
ACCESSION NUMBER:		0001193125-16-528595
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160404
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160404
DATE AS OF CHANGE:		20160404

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			REPLIGEN CORP
		CENTRAL INDEX KEY:			0000730272
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				042729386
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-14656
		FILM NUMBER:		161548957

	BUSINESS ADDRESS:	
		STREET 1:		41 SEYON STREET
		STREET 2:		BUILDING 1, SUITE 100
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453
		BUSINESS PHONE:		7814499560

	MAIL ADDRESS:	
		STREET 1:		41 SEYON STREET
		STREET 2:		BUILDING 1, SUITE 100
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d174826d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): April&nbsp;4, 2016 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>REPLIGEN CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>0-14656</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>04-2729386</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>41 Seyon Street, Bldg. 1, Suite 100, Waltham, MA 02453 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of Principal Executive Offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(781) 250-0111 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (<I>see </I>General Instruction A.2. below): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;3.02 Unregistered Sale of Equity Securities. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Share Purchase Agreement described in Item&nbsp;8.01 of this Current Report on Form 8-K, which description is incorporated herein by reference,
on the April&nbsp;1, 2016, in connection with the closing of the Transaction described in Item&nbsp;8.01 below, Repligen Corporation (the &#147;Company&#148;) issued and contributed 538,700 shares of the Company&#146;s common stock, par value of
$0.01 per share (the &#147;Stock Consideration&#148;) to Repligen Sweden AB, a wholly-owned subsidiary of the Company (&#147;Repligen Sweden&#148;), through a transfer by the Company on behalf of Repligen Sweden to fulfill Repligen Sweden&#146;s
obligation to deliver the Stock Consideration under the Share Purchase Agreement. The issuance of the Stock Consideration will not be registered under the Securities Act of 1933 (the &#147;Securities Act&#148;), in reliance upon the exemption from
registration provided by Section&nbsp;4(2) of the Securities Act. The Stock Consideration was based on a share price $24.97, representing the 10-day weighted average closing price of Repligen stock at market close on March&nbsp;29, 2016.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;7.01 Regulation FD Disclosure. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
April&nbsp;4, 2016, the Company issued a press release announcing the Transaction described in Item&nbsp;8.01. This press release is attached to this Current Report on Form 8-K and furnished as Exhibit 99.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in this Item&nbsp;7.01 of this Form 8-K and Exhibit 99.1 attached hereto shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18
of the Exchange Act or otherwise subject to the liabilities of that section, nor shall any of it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in
such a filing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;8.01. Other Events. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
April&nbsp;1, 2016, Repligen Sweden acquired Atoll GmbH from UV-Cap GmbH&nbsp;&amp; Co. KG (the &#147;Seller&#148;) pursuant to a Share Purchase Agreement (the &#147;Share Purchase Agreement&#148;), dated as of March&nbsp;31, 2016 (such acquisition,
the &#147;Transaction&#148;), by and among Repligen Sweden, the Seller, and the Company, in its capacity as guarantor of the obligations of Repligen Sweden under the Share Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the closing of the Transaction, Repligen Sweden paid to the Seller in consideration for all of the equity interests in Atoll GmbH a purchase price of
$9.1&nbsp;million in cash (the &#147;Cash Consideration&#148;) and the Share Consideration, in each case subject to certain adjustments. The Share Purchase Agreement includes a future contingent payment by Repligen Sweden to the Seller consisting of
&#128;1.0&nbsp;million in cash (the &#147;Earnout Consideration&#148;) if certain Atoll GmbH revenue increases by a specified amount from calendar year 2015 to calendar year 2016. A portion of the Cash Consideration and a portion of the Stock
Consideration were contributed to a third-party escrow fund against which Repligen Sweden may make indemnification claims. The Share Purchase Agreement further provides that Repligen Sweden will be entitled to offset any indemnifiable losses against
the Earnout Consideration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I></I>(d) <I>Exhibits.</I> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:23.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release by Repligen Corporation, dated April 4, 2016.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">REPLIGEN CORPORATION</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: April&nbsp;4, 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Tony J. Hunt</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Tony J. Hunt</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President and Chief Executive Officer</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:23.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release by Repligen Corporation, dated April 4, 2016.</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d174826dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g174826snap1.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Repligen
Corporation</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;41 Seyon
Street</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Building #1,
Suite 100</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Waltham,
Massachusetts 02453</P></TD></TR>
</TABLE> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Repligen Acquires Atoll GmbH </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- Broadens portfolio, expands customer base and increases capabilities in </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">growing pre-packed chromatography column market - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WALTHAM, MA &#150; April&nbsp;4, 2016 &#150; </B>Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology
leadership, today announced that it has acquired Atoll GmBH (&#147;Atoll&#148;) of Weingarten, Germany, an innovator and manufacturer of MediaScout<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> pre-packed chromatography columns used in
process development and clinical manufacturing of biologic drugs. The acquisition of Atoll expands Repligen&#146;s pre-packed column chromatography portfolio into high throughput process development screening, complementing the Company&#146;s
existing strength in clinical production-scale columns. The combined offering will provide bioprocessing customers with breadth and flexibility in choosing column size, chromatography media and packed bed formats. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Repligen purchased Atoll from UV-Cap GmbH &amp; Co. KG on April&nbsp;1, 2016 for a combination of $9.1 million in cash and 538,700 shares<SUP
STYLE="font-size:85%; vertical-align:top">1</SUP> of Repligen common stock, for total upfront consideration of approximately $22.5 million. The agreement also includes a potential payment of &#128;1.0&nbsp;million, contingent on achieving a
predetermined revenue target for the year 2016. The Company expects sales of Atoll products to add approximately $3.0-$3.5 million in revenue for the remaining nine months of 2016, and to be break-even on adjusted EPS, which excludes transaction and
integration costs by year-end 2016. The Company expects the acquisition to be EPS accretive, on a GAAP basis, in 2017. Repligen was assisted in this transaction by EC Mergers and Acquisitions, a EuroConsult company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Atoll&#146;s MediaScout family of products is a market and technology fit for Repligen that complements our growing OPUS<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> product line of pre-packed disposable chromatography columns,&#148; said Tony J. Hunt, President and Chief Executive Officer of Repligen. &#147;This acquisition extends our reach into the
screening and process development labs where single-use platform technologies are evaluated and adopted. As we look to the future, we see the Weingarten facility as our European commercial and manufacturing center for many of our high-value and
flexible solutions for the bioprocessing industry.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Martin Reuter, Managing Director of Atoll said, &#147;The MediaScout product line has
experienced accelerating demand over the last few years. The synergies with Repligen, and OPUS in particular, are clear. We look forward to joining forces to increase the adoption of MediaScout products and drive further adoption of a broader
portfolio of pre-packed columns in the bioprocessing market.&#148; </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The number of shares issued was based on a share price $24.97, representing the 10-day weighted average closing price of Repligen stock at market close on March&nbsp;29, 2016. </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Repligen Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Repligen Corporation (NASDAQ:RGEN) is a life sciences company focused on the development and commercialization of high-value bioprocessing products used to
manufacture biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are the leading manufacturer of Protein A affinity ligands, a critical component of Protein A media that is used
to separate and purify monoclonal antibody therapeutics. Our ATF System and our growth factor products are used to increase product yield during the fermentation stage of biologic drug manufacturing. In addition, we developed and market an
innovative line of &#147;ready-to-use&#148; chromatography columns under our OPUS<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> brand that we deliver pre-packed with our customers&#146; choice of purification media. Repligen&#146;s
corporate headquarters are in Waltham, MA (USA) and our manufacturing facilities are located in Waltham, MA and Lund, Sweden. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following
constitutes a &#147;Safe Harbor&#148; statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of Section&nbsp;27A of the
Securities Act of 1933, as amended, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that statements in this press release which are not strictly historical statements, constitute forward-looking
statements, including, without limitation, express or implied statements or guidance regarding future financial performance of Atoll product revenue, customer adoption of the MediaScout and OPUS product lines, future financial performance of
Repligen, including the accretive nature of the Atoll acquisition, expected synergies following the acquisition of Atoll, Atoll&#146;s Weingarten facility serving as Repligen&#146;s European commercial and manufacturing center and other statements
identified by words like &#147;believe,&#148; &#147;expect,&#148; &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;seek,&#148; &#147;anticipate,&#148; or &#147;could&#148; and similar expressions. Such forward-looking statements are
subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: our ability to integrate Atoll&#146;s business and personnel and to
achieve expected synergies; our ability to maintain or expand Atoll&#146;s historical sales; our ability to accurately forecast the acquisition, related restructuring costs and allocation of the purchase price, goodwill and other intangibles
acquisition related and other asset adjustments; our ability to develop and commercialize products and the market acceptance of our products; reduced demand for single-use or disposable bioprocessing products that adversely impacts our future
revenues, cash flows, results of operations and financial condition; our volatile stock price; and other risks detailed in Repligen&#146;s most recent Annual Report on Form 10-K on file with the Securities and Exchange Commission and the other
reports that Repligen periodically files with the Securities and Exchange Commission. Actual results may differ materially from those Repligen contemplated by these forward-looking statements. These forward looking statements reflect
management&#146;s current views and Repligen does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date hereof except as required by law. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sondra S. Newman </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Director Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Repligen Corporation </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(781) 419-1881 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>snewman@repligen.com</U> </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g174826snap1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g174826snap1.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MA0G/FHR48VE"$IKVD)R:YHRJ59PYKQ?)"2E3_%3ST_R17ZOSQ/S#V4C];/V
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MK^SOX4T'QOXOT3POK7_"I/[9\-Z1XEUG3=!U;^T?BQX@TW4?[3T>SO8[2_\
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,@ H * "@ H * /_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
